


Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:


Claims 1-26 (cancelled).

27. (currently amended) A compound according to ~~Claim 4~~ of formula I



or a pharmaceutically-acceptable salt or prodrug thereof.

wherein R¹ is haloalkyl; R² is haloalkyl; R³ is trans-cinnamide wherein trans-cinnamide is defined as



"trans-cinnamide"

wherein R⁸ and R⁹ are hydrogen and R¹⁰ and R¹¹ together with N are heterocyclyl; R⁴ is hydrogen; R⁵ is hydrogen; and Ar is aryl, wherein the aryl is substituted with a substituted heterocyclyl,

wherein the heterocyclyl is chosen from 4-, 5-, 6- and 7-membered rings containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 4- and 5-membered rings have zero to two double bonds and the 6-



Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

and 7-membered rings have zero to three double bonds, the heterocyclyl being optionally substituted with alkyl, halogen, hydroxy or alkoxy substituents,

wherein the heterocyclyl optionally comprises a group chosen from:

(i) bicyclic, tricyclic and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, and another monocyclic heterocyclic ring;

(ii) bridged bicyclic groups where a monocyclic heterocyclic group is optionally bridged by an alkylene group selected from



(iii) compounds of the formula where X* and Z* are independently selected from -CH₂-, -CH₂NH-, -CH₂O-, -NH- and -O-, with the proviso that at least one of X* and Z* is not -CH₂-, and Y* is selected from -C(O)- and -(C(R''))_v-, where R'' is hydrogen or alkyl of one to four carbons, and v is 1-3;

and wherein aryl is defined as a mono- or bicyclic carbocyclic, aromatic ring.

Application No.: 10/725,212
 Attorney Docket No. 09095.0006-01


28. (currently amended) A compound according to Claim ~~[[1]]~~ 27 wherein R^1 is trifluoromethyl; R^2 is trifluoromethyl; R^3 is trans-cinnamide wherein R^8 and R^9 are hydrogen and R^{10} and R^{11} together with N are morpholino; R^4 is hydrogen; R^5 is hydrogen; and Ar is phenyl, wherein the phenyl is substituted with substituted piperidine.

29. (currently amended) A compound according to Claim ~~[[12]]~~ 28 that is [3-(3-carboxypiperidin-1-yl)phenyl] [2,3-bis(trifluoromethyl)-4-(E-((4-morpholino)carbonyl)ethenyl)phenyl]sulfide.

30. (currently amended) A compound according to Claim ~~[[12]]~~ 28 that is (R)-[3-(3-carboxypiperidin-1-yl)phenyl] [2,3-bis(trifluoromethyl)-4-(E-((4-morpholino)carbonyl)ethenyl)phenyl]sulfide.

31. (currently amended) A compound according to Claim ~~[[12]]~~ 28 that is (S)-[3-(3-carboxypiperidin-1-yl)phenyl] [2,3-bis(trifluoromethyl)-4-(E-((4-morpholino)carbonyl)ethenyl)phenyl]sulfide.

32. (currently amended) A method of treating cerebral vasospasm comprising the administration of a compound of Claim 1 to a mammal in need of treatment, of a therapeutically effective amount of a compound of formula I



or a pharmaceutically-acceptable salt or prodrug thereof.


Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

wherein R_1 , R_2 , R_3 , R_4 , and R_5 are independently selected from

- a. hydrogen,
- b. halogen,
- c. alkyl,
- d. haloalkyl,
- e. alkoxy,
- f. cyano,
- g. nitro,
- h. carboxaldehyde, and

with the proviso that at least one of R_1 or R_3 is a "cis-cinnamide" or a

"trans-cinnamide", defined as



wherein R_8 and R_9 are independently selected from

- a. hydrogen,
- b. alkyl,
- c. carboxy alkyl,
- d. alkylaminocarbonyl alkyl, and
- e. dialkylaminocarbonyl alkyl,

wherein R_{10} and R_{11} are independently selected from

Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

- a. hydrogen,
- b. alkyl,
- c. cycloalkyl,
- d. alkoxycarbonylalkyl,
- e. hydroxyalkyl,
- f. substituted aryl,
- g. heterocyclyl,
- h. heterocyclylalkyl,
- i. heterocyclylamino,
- j. substituted heterocyclyl, and
- k. substituted heterocyclylalkyl,

or wherein NR₁₀R₁₁ is heterocyclyl or substituted heterocyclyl, where
substituents are independently selected from

- 1) alkyl,
- 2) alkoxy,
- 3) alkoxyalkyl,
- 4) cycloalkyl,
- 5) aryl,
- 6) heterocyclyl,
- 7) heterocyclylcarbonyl,
- 8) heterocyclylalkylaminocarbonyl,
- 9) hydroxy,
- 10) hydroxyalkyl,

Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

- 11) hydroxyalkoxyalkyl,
- 12) carboxy,
- 13) carboxyalkyl,
- 14) carboxycarbonyl,
- 15) carboxaldehyde,
- 16) alkoxycarbonyl,
- 17) arylalkoxycarbonyl,
- 18) aminoalkyl,
- 19) aminoalkanoyl,
- 20) carboxamido,
- 21) alkoxycarbonylalkyl,
- 22) carboxamidoalkyl,
- 23) cyano,
- 24) tetrazolyl,
- 25) substituted tetrazolyl,
- 26) alkanoyl,
- 27) hydroxyalkanoyl,
- 28) alkanoyloxy,
- 29) alkanoylamino,
- 30) alkanoyloxyalkyl,
- 31) alkanoylaminoalkyl,
- 32) sulfonate,
- 33) alkylsulfonyl,

Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

34) alkylsulfonylaminocarbonyl,

35) arylsulfonylaminocarbonyl, and

36) heterocyclysulfonylaminocarbonyl,

wherein Ar is a substituted aryl or substituted heteroaryl group, where
substitutions are independently selected from

a. hydrogen,

b. halogen,

c. alkyl,

d. aryl,

e. haloalkyl,

f. hydroxy,

g. alkoxy,

h. alkoxyalkyl,

i. alkoxycarbonyl,

j. alkoxyalkoxy,

k. hydroxyalkyl,

l. aminoalkyl,

m. aminocarbonyl,

n. alkyl(alkoxycarbonylalkyl)aminoalkyl,

o. heterocyclyl,

p. substituted heterocyclyl,

q. heterocyclylalkyl,

r. substituted heterocyclylalkyl,

Application No.: 10/725,212
Attorney Docket No. 09095.0006-01



- s. carboxaldehyde,
- t. carboxaldehyde hydrazone,
- u. carboxamide,
- v. alkoxycarbonylalkyl,
- w. carboxy,
- x. carboxyalkyl,
- y. carboxyalkoxy,
- z. carboxythioalkoxy,
- aa. carboxycycloalkoxy,
- bb. thioalkyl,
- cc. hydroxycarbonylalkyl (carboxyalkyl),
- dd. hydroxyalkylaminocarbonyl,
- ee. cyano,
- ff. amino,
- gg. heterocyclylalkylamino,
- hh. carboxyalkylamino,
- ii. heterocyclylalkylaminocarbonyl, and
- li. "trans-cinnamide," and


wherein the heterocyclyl is chosen from 4-, 5-, 6- and 7-membered rings containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds, the heterocyclyl being optionally substituted with alkyl, halogen, hydroxy or alkoxy substituents,

Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

wherein the heterocyclyl optionally comprises a group chosen from:

- (i) bicyclic, tricyclic and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, and another monocyclic heterocyclic ring;
- (ii) bridged bicyclic groups where a monocyclic heterocyclic group is optionally bridged by an alkylene group selected from



- (iii) compounds of the formula  where X* and Z* are independently selected from -CH₂-, -CH₂NH-, -CH₂O-, -NH- and -O-, with the proviso that at least one of X* and Z* is not -CH₂-, and Y* is selected from -C(O)- and -(C(R''))_v-, where R'' is hydrogen or alkyl of one to four carbons, and v is 1-3;

wherein aryl is defined as a mono- or bicyclic carbocyclic, aromatic ring,
and wherein the compound is administered orally, rectally, parenterally,
intracisternally, intravaginally, intraperitoneally, topically, buccally, or as an oral or
nasal spray.

Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

33. (currently amended) A method of treating cerebral vasospasm according to Claim 32 comprising the administration of a composition of Claim 19 to a mammal in need of treatment, wherein the compound is administered as a part of a composition, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.